A Population-Based Study on the Prognostic factors and Efficacy of Adjuvant Chemotherapy in the Postoperative Stage for Patients with Stage IIA Non-Small Cell Lung Cancer
DOI: https://doi.org/10.2147/RMHP.S373510
2022-08-25
Risk Management and Healthcare Policy
Abstract:Wei Wang, * Fei Teng, * Shi Bu, Wei Xu, Qing-Chun Cai, Yue-Quan Jiang, Zhi-Qiang Wang Key Laboratory for Biorheological Science and Technology of Ministry of Education (Chongqing University), Chongqing University Cancer Hospital, Chongqing, 400030, China *These authors contributed equally to this work Correspondence: Yue-Quan Jiang; Zhi-Qiang Wang, Key Laboratory for Biorheological Science and Technology of Ministry of Education (Chongqing University), Chongqing University Cancer Hospital, No. 181 of Hanyu Road, Shapingba District, Chongqing, 400030, China, Tel +86 13708335256 ; +86 15215023098, Email ; Objective: This study aimed to design a nomogram survival prediction by means of the figures retrieved from the Surveillance, Epidemiology, and End Results (SEER) source bank, and to predict the overall survival (OS) of patients with stage IIA non-small cell lung cancer (NSCLC) after surgery. Methods: Data for 4511 patients who had been diagnosed with postoperative stage IIA NSCLC were collected from the SEER databank, while information on 528 patients was acquired from the Chongqing University Cancer Hospital for the external validation cohort. The independent risk factors that affected the prognosis were identified using a multivariate Cox proportional hazards regression model (also used to conduct a nomogram). A survival analysis between the low- and the high-risk groups was performed using the Kaplan–Meier method. Furthermore, a subgroup analysis was conducted of the two groups using the Kaplan–Meier method to determine whether the patients had received adjuvant chemotherapy. Results: The following five variables were integrated into the nomogram: sex (female: HR 1.73, 95% CI 0.64– 0.83), age (≥ 60: HR 1.61, 95% CI 1.39– 1.87), differentiation grade (grade II: HR 2.19, 95% CI 1.66– 2.88; grade III: HR 2.65, 95% CI 2.00– 3.51; grade IV: HR 3.17, 95% CI 1.99– 5.03), surgery (lobectomy: HR 0.72, 95% CI 0.59– 0.86), and lymph node resection (> 12: HR 0.82, 95% CI 0.70– 0.96). Furthermore, the patients selected were categorized into high- and low-risk groups. The OS rate was significantly lower in the high-risk group than in the low-risk group (P < 0.001). Finally, adjuvant chemotherapy was highly correlated with OS in the high-risk set (P = 0.035); however, adjuvant chemotherapy was not related to OS in the low-risk set. Conclusion: A nomogram was created as a reliable, convenient scheme that could predict OS, and it was determined that the high-risk feature patients identified by the nomogram gained benefits from adjuvant chemotherapy. Keywords: nomogram, stage IIA non-small cell lung cancer, adjuvant chemotherapy, OS prediction Lung carcinoma is a malicious tumor, affecting people globally, of which the incidence and mortality rate rank first among cancers. 1,2 Over 80% of pulmonary cancer cases are non-small cell lung cancer (NSCLC). 3 The overall five-year survival rate of NSCLC is only about 15%, 4 posing a significant public health threat. Therefore, appropriate adjuvant treatment for lung cancer after surgery is important for the prognosis. 5,6 Stage I lung cancer usually does not require postoperative adjuvant therapy due to its good prognosis. Adjuvant chemotherapy or even combined with radiotherapy is routinely recommended for patients with intermediate stage and above lung cancer. However, stage IIA lung cancer is at the junction of early-stage lung cancer and intermediate-stage lung cancer, and whether it can benefit from postoperative adjuvant chemotherapy is still controversial. 7 According to the 8th edition of NCCN guidelines, conventional adjuvant chemotherapy is not recommended after surgery for stage IIA lung cancer, and adjuvant chemotherapy is only suitable for patients with high risk factors, such as pleural invasion, tumors larger than 4 cm, perineural invasion, and vascular invasion. The single risk factor method may not be sufficiently reliable to screen patients with postoperative stage IIA NSCLC who need adjuvant chemotherapy, resulting in possible overtreatment or undertreatment. Therefore, it is important to develop a prognostic model that incorporates more risk factors to accurately identify high-risk groups after surgery for stage IIA lung cancer, and to assess whether patients can benefit from adjuvant chemotherapy based on this model. Currently, the nomogram is considered an effective instrument to evaluate risks by considering vital clinical and pathological features in cancer diagnoses. 8,9 By creating a simple and efficient evaluation structure, these well-used graphs could help practitioners and patients implement an appropriate and personalized therapeutic regimen. Additionally, the nomogram -Abstract Truncated-
health care sciences & services,health policy & services